公开(公告)号：US11111293B2

公开(公告)日：2021-09-07

申请号：US16111659

申请日：2018-08-24

Applicant: NOVARTIS AG

Inventor： Michael Otto Bardroff ,  Barbara Brannetti ,  Emma Michelle Campbell ,  Beate Diefenbach-Streiber ,  Adina Eberth ,  Christian Carsten Silverster Kunz ,  Sylwia Marshall ,  Jean-Michel Rene Rondeau ,  Jean-Marc Alfred Schlaeppi ,  Gino Anselmus Van Heeke

IPC: C07K16/24 ,  G01N33/68 ,  C12P21/00

Abstract: Interleukin-18 (IL-18) participates in both innate and acquired immunity. The bioactivity of IL-18 is negatively regulated by the IL-18 binding protein (IL18BP), a naturally occurring and highly specific inhibitor. This soluble protein forms a complex with free IL-18 preventing its interaction with the IL-18 receptor, thus neutralizing and inhibiting its biological activity. The present invention discloses binding molecules, in particular antibodies or fragments thereof, which bind IL-18 and do not bind IL-18 bound to IL-18BP (IL-18/IL-18BP complex). Apart from its physiological role, IL-18 has been shown to mediate a variety of autoimmune and inflammatory diseases. The binding molecules of the inventions may be used as therapeutic molecules for treating IL-18-related autoimmune and inflammatory diseases or as diagnostic tools for characterizing, detecting and/or measuring IL-18 not bound to IL-18BP as component of the total IL-18 pool.

公开(公告)号：US11987644B2

公开(公告)日：2024-05-21

申请号：US16844999

申请日：2020-04-09

Applicant: NOVARTIS AG

Inventor： Michael Otto Bardroff ,  Tina Buch ,  Christian Graf ,  Daniel Heitmann ,  Thomas Jostock ,  Hans-Peter Knopf ,  Rolf Koehler ,  Jiri Kovarik ,  Stephen John Oliver ,  Dhavalkumar Patel ,  Maximilian Woisetschlaeger

IPC: C07K16/00 ,  A61P1/00 ,  A61P9/00 ,  A61P9/10 ,  A61P9/14 ,  C07K16/24 ,  C07K16/28 ,  C07K16/46

CPC classification number: C07K16/468 ,  A61P1/00 ,  A61P9/10 ,  A61P9/14 ,  C07K16/00 ,  C07K16/244 ,  C07K16/245 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2319/00

Abstract: The invention relates to bivalent bispecific monoclonal antibodies (bbmAb) or variants thereof, and methods of manufacturing such antibodies by co-expressing modified Fc-mutated derivatives of two different monoclonal antibodies in mammalian cell lines.